Glucagon agonist how to use in obesity
Reading File
Now I'll search the medical library and PubMed in parallel for glucagon agonists in obesity.
Finding Sources
Finding Sources
Searching PubMed
glucagon receptor agonist obesity treatment
Searching the Web
glucagon agonist obesity treatment 2025 GLP-1 dual triple agonist
Now let me read the key textbook sections in parallel for detailed content.
Reading File
Reading File
Reading File
Reading Article
PMID: 37366315
Now let me get the Katzung section on glutiides/GLP-1 in obesity and the Harrison's GLP-1 RA obesity pharmacotherapy section.
Reading File
Reading File
I now have comprehensive information to provide a thorough, well-structured answer. Let me synthesize everything.
Glucagon-Related Agonists in Obesity Management
Clarifying the Terminology
"Glucagon agonist" in the obesity context most commonly refers to GLP-1 (glucagon-like peptide-1) receptor agonists — peptides derived from the proglucagon gene, like glucagon itself, but acting on a distinct receptor. The term also increasingly covers dual and triple agonists that co-target the glucagon receptor alongside GLP-1 and GIP receptors. The pure glucagon receptor agonist as a stand-alone obesity agent is still experimental.
1. GLP-1 Receptor Agonists (GLP-1 RAs)
Mechanism
GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food. GLP-1 RAs reduce body weight by:
- Slowing gastric emptying → prolonged satiety
- Acting on hypothalamic appetite-regulation centers → reduced hunger
- Stimulating glucose-dependent insulin secretion + inhibiting glucagon secretion
- Increasing energy expenditure
FDA-Approved Agents for Obesity
| Drug | Receptor | Route | Dosing | Placebo-Subtracted Weight Loss |
|---|---|---|---|---|
| Liraglutide (Saxenda) | GLP-1 | SC once daily | Start 0.6 mg/day → titrate to 3 mg/day over 5 weeks | ~5.4% |
| Semaglutide (Wegovy) | GLP-1 | SC once weekly | Start 0.25 mg/wk → titrate over 16–20 weeks to 2.4 mg/wk | ~12.5% |
| Tirzepatide (Zepbound) | GLP-1 + GIP (dual) | SC once weekly | Start 2.5 mg/wk → titrate every 4 weeks to max 15 mg/wk | ~17.8% |
Data from Harrison's 22E (2025), Sabiston Textbook of Surgery, and SURMOUNT/STEP trials
2. How to Use Each Agent
Liraglutide 3 mg (Saxenda)
- Indication: BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity
- Dose escalation (SC, once daily):
- Week 1: 0.6 mg/day
- Week 2: 1.2 mg/day
- Week 3: 1.8 mg/day
- Week 4: 2.4 mg/day
- Week 5 onward: 3.0 mg/day (maintenance)
- Expected weight loss: ~6% above placebo at 56 weeks
- Discontinue if < 4% weight loss by week 16
Semaglutide 2.4 mg (Wegovy)
- Indication: Same BMI criteria as liraglutide
- Dose escalation (SC, once weekly):
- Weeks 1–4: 0.25 mg/wk
- Weeks 5–8: 0.5 mg/wk
- Weeks 9–12: 1.0 mg/wk
- Weeks 13–16: 1.7 mg/wk
- Week 17+: 2.4 mg/wk (maintenance)
- Oral semaglutide (Rybelsus, 3→7→14 mg/day) is also available for T2DM and has weight-loss benefit, though lower than injectable
- Expected weight loss: ~15% total body weight (STEP trials); SELECT trial showed 20% reduction in MACE in overweight/obese without diabetes
- Discontinue if < 5% weight loss by week 16
Tirzepatide (Zepbound) — Dual GIP/GLP-1
- Indication: Same BMI criteria; also approved for obstructive sleep apnea with obesity and HFpEF with obesity
- Dose escalation (SC, once weekly):
- Weeks 1–4: 2.5 mg/wk
- Weeks 5–8: 5 mg/wk
- Weeks 9–12: 7.5 mg/wk
- Weeks 13–16: 10 mg/wk
- Weeks 17–20: 12.5 mg/wk
- Week 21+: 15 mg/wk (maximum)
- Expected weight loss: ~20–22% total body weight (SURMOUNT-1); up to 24% when continued after initial period (SURMOUNT-4)
- The GIP component adds synergistic insulin sensitization and further appetite suppression beyond GLP-1 alone
3. The Pure Glucagon Receptor Angle: Dual & Triple Agonists
Glucagon receptor co-agonism is specifically being incorporated into next-generation agents because glucagon:
- Stimulates hepatic fat oxidation and thermogenesis
- Increases energy expenditure (brown adipose tissue activation)
- Promotes hepatic lipid clearance
Retatrutide (Investigational — Phase 2/3)
A triple agonist (GIP + GLP-1 + glucagon receptor):
- Phase 2 RCT (NEJM 2023, PMID 37366315) showed 24.2% weight loss at 48 weeks with 12 mg dose
- 100% of participants on 8–12 mg achieved ≥5% weight loss; 83–93% achieved ≥15%
- SC once weekly; dose-dependent GI side effects (nausea, vomiting) were partially mitigated with lower starting dose (2 mg)
- Phase 3 trials ongoing
4. Key Contraindications (All GLP-1 Class)
- Personal or family history of medullary thyroid carcinoma
- MEN type 2 syndrome
- History of pancreatitis (caution)
- Pregnancy
- Severe renal or hepatic impairment (dose-dependent consideration)
5. Common Adverse Effects
- GI dominant: Nausea, vomiting, diarrhea, constipation, dyspepsia — most prominent during dose escalation; resolve with slower titration
- Dose reduction or slowing titration recommended if intolerable GI effects
- Retatrutide/triple agonists additionally showed dose-dependent heart rate increase (peaked at 24 weeks, then declined)
6. Practical Clinical Guidance
| Scenario | Preferred Agent |
|---|---|
| Max weight loss needed | Tirzepatide (or retatrutide when available) |
| Obesity + T2DM | Tirzepatide or semaglutide (dual benefit) |
| Obesity + established CVD | Semaglutide (SELECT trial CV benefit proven) |
| Obesity + OSA | Tirzepatide (NEJM 2024, PMID 38912654) |
| Obesity + HFpEF | Tirzepatide (NEJM 2025, PMID 39555826) |
| Post-bariatric surgery with weight regain | Semaglutide preferred over liraglutide (meta-analysis: ~10% additional loss) |
| Bridge to bariatric surgery (high BMI) | Any GLP-1 RA to reduce surgical risk |
⚠️ Important: Weight regain occurs rapidly on discontinuation — approximately two-thirds of lost weight returns within 1 year of stopping. Treatment should be considered long-term/indefinite, similar to antihypertensives or statins. (Meta-analysis, Obes Rev 2025, PMID 40186344)
Summary
The "glucagon agonist" family in obesity spans a spectrum from pure GLP-1 RAs (liraglutide, semaglutide) to dual GIP/GLP-1 agonists (tirzepatide) to triple GIP/GLP-1/glucagon agonists (retatrutide — investigational). The progression up this spectrum delivers progressively greater weight loss, largely because co-agonism at the glucagon receptor adds thermogenic and hepatic fat-burning effects to the appetite suppression of GLP-1. All agents require gradual dose escalation, SC administration (except oral semaglutide), and should be paired with lifestyle modification.
This is a shared conversation. Sign in to Orris to start your own chat.